Globally, various vaccines against Govt-19 are already approved by regulatory bodies for immunization and drug control in countries. There are more 105 Vaccine candidates are evaluated in clinical trials, and 41 They have reached the final evaluation stage. Meanwhile, more than 6.8 billion volumes have already been used on the planet. And a panel of experts from the World Health Organization added a new vaccine to its list of emergency vaccines: Approved Kovac vaccine developed by Bharat Biotech, an Indian company. In total, the WHO health agency has already approved 7 vaccines against COVID-19. But it is still in the estimate for other vaccines already used by more than 4,000 million people.
Vaccines against Govt-19 can be approved in two ways. Once approved by the National Regulatory Authority. Vaccine makers provide information on their effectiveness in preventing disease through clinical trials. National regulatory authorities examine this data to assess whether accreditation is required. The effectiveness and safety of vaccines are constantly monitored even after the vaccines are introduced in a country.
On the other hand, there is the practice of adding it to the WHO list for emergency use. “In order to expedite the availability of these products to people affected by public health emergencies, it is a risk-based process to evaluate and list unlicensed vaccines, treatments and in vitro diagnoses,” he explained. Health Institute. This process allows countries to import and administer COVID-19 vaccines and expedite their own regulatory accreditation.
Countries and national regulatory authorities can approve the use of the COVID-19 vaccine in a country, even if it is not listed by the WHO for emergency use. Because “Each member state has a sovereign duty to its own citizens and develops its own national health policies,” the health agency acknowledges.
Approval from the health agency comes after a vaccine and immunization advisory panel called SAGE has been issued. It advises the WHO on global policies and strategies ranging from vaccine and immunization technology, research and development, immunization implementation and its links to other health interventions. The role of the advisory board is beyond Govt-19. It treats all diseases that can be prevented by vaccination.
The messenger RNA vaccine developed by Pfizer / BioNTEch is the first vaccine to be approved by the United Nations Health Organization. It was first recognized in adults. The vaccine was developed in the United States and Germany and has been used in countries such as Chile and Argentina (since last October). In a third phase trial involving children 12 to 15 years of age, the vaccine was found to be most effective and most safe for this age group. As a result, the previous symptom was limited to children 16 years of age and older, and is recommended for children 12 years of age and older.
Director, Centers for Disease Control and Prevention (CDC), USA Dr. Rochelle Valensky said yesterday that they had approved the company’s advisory board’s recommendation to vaccinate children between the ages of 5 and 11 with the Pfizer / Bioentech vaccine. Clarifies the way to get vaccinated immediately for this age group in the United States, even younger.
The second vaccine approved by the World Health Organization is based on the Messenger RNA site. It was developed by a modern company in the United States. It is already approved in that country, Canada, and in Australia in September it was approved for teenagers. It has been used in Argentina since August for adolescents with risk factors and adults waiting for a second dose. Sputnik V vaccine, delivery delayed.
Approval for the adenovirus vector vaccine developed by Astrogeneka in the United Kingdom and its Covshield version of the Serum is a single-dose vaccine from the Johnson & Johnson / Johnson Institute (licensed in 75 countries). Inactivated vaccines developed in China by Sinovac Biotech and Sinoform.
Last October, The WHO SAGE team has renewed its approval for two Chinese vaccines. “For synovial and sinoform inactivated vaccines, an additional (third) dose of homologous vaccine should be given to those 60 years of age and older as part of an extended primary series. The use of a multi-platform vaccine for additional dose may also be considered based on vaccine delivery and access considerations. In implementing this recommendation, countries should first aim to increase the coverage of two doses in that population, and then administer a third dose, starting with the elderly, ”the panel’s experts wrote. In countries such as Argentina, people over the age of 50 who have been vaccinated with the synoform vaccine will receive additional medication. Also children and adults with immunodeficiency will receive the third dose.
The vaccine developed in India is included in the list today, they call it covaxin. The WHO found that it was 78% effective in preventing severe COVID-19 and was “extremely effective” for poor countries due to its simple storage conditions.
In the meantime, The Sputnik V vaccine, developed by the Russian company Kamaleya, is still being evaluated by the SAGE Group.. It is already recognized in 70 countries. During a recent press conference, WHO Deputy Director-General for Access to Drugs, Vaccines and Pharmaceuticals Dr. Mariangela Simovo noted that the Sputnik V emergency application list process was suspended until October 20 “due to legal procedure”. To proceed with the assessment, the applicant is required to sign that he or she has accepted the WHO’s rules and procedures.
The Sputnik V vaccine evaluation process resumed on October 21, so inspections of the drug-producing plants may resume in the coming weeks. “We will continue to receive additional data from Sputnik clients. So it is a process that works for everyone, ”he added.
The waiting time for a vaccine to be added to the WHO list “depends on how quickly the manufacturers send the data,” said Dr. Simov says. “In some cases, we have to do factory inspections,” he added.
The CanSino Biologics single-dose vaccine developed in China is also awaiting WHO approval. It has not yet been approved by the WHO, however. Although the administrative procedures have been completed, there is no exact date for approval. It is already recognized in countries like Argentina.
The CanSino Biologics vaccine uses the same technology as the Ebola vaccine, which contains virus vectors (genetic material) and weakens viruses used as vehicles. As a result, they are less likely to develop Govit-19 disease. Upon receipt of the vaccine, the virus vector will produce hundreds of copies of the antigen, thus the immune system responds with neutral antibodies after 14 days.
“Introvert. Thinker. Problem solver. Evil beer specialist. Prone to fits of apathy. Social media expert. Award-winning food fanatic.”